The Malaria Consortium
Rees Calder · 26 April 2026 · 6 min read
Most malaria interventions wait for the disease to arrive. Bed nets create a barrier. Rapid diagnostic tests catch infections early. Artemisinin-based treatments fight the parasite once it's in your blood. All of these are reactive.
Seasonal malaria chemoprevention (SMC) is different. It gives healthy children a course of preventive antimalarial drugs before the rainy season, when malaria transmission peaks. The drugs (sulfadoxine-pyrimethamine plus amodiaquine, administered monthly for 3-4 months) prevent infection entirely during the highest-risk period. It's a vaccine-like approach without a vaccine: you take the treatment before you're sick.
The Malaria Consortium is the leading implementer of SMC globally, and one of GiveWell's top-rated charities. In 2023, they treated approximately 45 million children across 13 countries in the Sahel and sub-Sahel regions of Africa (Malaria Consortium Annual Report, 2024). The evidence base is strong, the cost is low, and the scale is genuinely impressive.
The evidence
The WHO recommended SMC in 2012 based on a systematic review of 12 randomised controlled trials. The Cochrane review (Meremikwu et al., 2012, updated 2022) found that SMC reduces clinical malaria episodes by approximately 75% during the transmission season. That's a larger effect size than almost any other malaria intervention, including bed nets (which reduce all-cause child mortality by roughly 17%).
The key qualification: SMC works specifically in areas with highly seasonal malaria transmission, where 60%+ of cases occur during a defined rainy season of 3-4 months. This is the Sahel pattern: Burkina Faso, Mali, Niger, Nigeria, Chad, Guinea, Senegal, The Gambia, and parts of neighbouring countries. In areas with year-round transmission (much of central Africa), SMC's seasonal approach doesn't apply.
Within its geographic sweet spot, the evidence is about as strong as it gets in public health. The ACCESS-SMC project (2015-2017), the largest implementation trial, treated 7.5 million children across seven countries and confirmed the trial results held at scale: 75% reduction in malaria episodes, significant reduction in severe malaria, and measurable reduction in all-cause mortality.
The cost-effectiveness case
GiveWell's 2024 cost-effectiveness analysis estimates the Malaria Consortium's SMC programme at roughly $7 per child per seasonal cycle (3-4 monthly treatments). In terms of cost per life saved, GiveWell estimates roughly $3,000-$5,000, making it comparable to or slightly more cost-effective than bed net distribution through the Against Malaria Foundation.
The cost breaks down roughly as: drugs (40%), delivery and community health worker costs (35%), supervision and monitoring (15%), and overhead (10%). The drugs themselves are cheap (roughly $0.50 per monthly dose). Most of the cost is getting them to children in remote rural areas during the rainy season, when roads become impassable and logistics become genuinely difficult.
The programme's cost-effectiveness has improved over time as the Malaria Consortium has scaled. Unit costs dropped roughly 25% between 2018 and 2023, primarily through better supply chain management and training of community health workers who deliver the drugs door-to-door.
What makes it work
Four implementation features worth understanding.
Community health workers. SMC is delivered door-to-door by trained community health workers (CHWs) who visit households during each monthly cycle. This model reaches children who would never visit a health clinic, including the most remote and poorest communities. The Malaria Consortium trains roughly 100,000 CHWs annually for SMC delivery (2024 data).
Directly observed treatment. The first dose of each monthly cycle is administered by the CHW in the household and observed. The remaining two days of treatment are left with the caregiver with instructions. Adherence to the full three-day course is roughly 85-90% (Malaria Consortium monitoring data, 2024), which is high for any drug regimen and critical for maintaining efficacy.
Integration with national health systems. Unlike some NGO-delivered programmes that create parallel structures, SMC is implemented through national malaria control programmes. The Malaria Consortium provides technical assistance, training, and drug procurement, but delivery runs through government health systems. This means the programme builds local capacity rather than replacing it.
Monitoring and pharmacovigilance. The Malaria Consortium tracks adverse events systematically. Serious adverse events from SMC drugs are rare (roughly 1 per 100,000 treatments), and the drugs have been on the WHO Essential Medicines List for decades. The monitoring data is shared with national regulatory authorities and published in annual reports.
The limitations, honestly
Geographic constraint. SMC only works in the seasonal malaria belt. This is roughly 300 million children at risk (WHO estimate). It's a lot, but it's not the entire malaria burden. Countries like the DRC and Mozambique, which carry some of the highest malaria burdens globally, have year-round transmission and can't use SMC.
Drug resistance risk. Any mass drug administration raises concerns about antimicrobial resistance. The WHO monitors resistance to sulfadoxine-pyrimethamine and amodiaquine across the Sahel. As of 2024, resistance levels remain below thresholds that would compromise efficacy, but the Malaria Consortium's own strategic plan acknowledges this as the primary long-term risk to the programme.
Not a permanent solution. SMC treats the symptom (seasonal malaria episodes) rather than the cause (mosquito-borne transmission). It needs to be repeated every year. The long-term solution is either malaria elimination (through a combination of vector control, treatment, and eventually vaccines) or sustained annual SMC delivery indefinitely. Neither is cheap.
Coverage gaps. Despite treating 45 million children in 2023, the Malaria Consortium estimates that roughly 30-40% of eligible children in their target countries were not reached, primarily due to insecurity in parts of the Sahel (northern Nigeria, Mali, Burkina Faso) and logistical constraints in the most remote areas.
How it complements other interventions
SMC doesn't replace bed nets or treatment. It stacks with them. The ACCESS-SMC data showed that children who both slept under nets and received SMC had roughly 85% fewer malaria episodes than children with neither intervention. The combination is more effective than either alone, and the costs are additive, not duplicative.
The R21/Matrix-M malaria vaccine (approved by WHO in 2023) adds another layer. The vaccine provides roughly 75% protection in the first year but efficacy wanes over subsequent years. The current WHO recommendation is for the vaccine AND continued SMC where seasonal transmission patterns exist. Over the next decade, the combination of vaccine, nets, and SMC may drive malaria mortality toward near-elimination levels in the Sahel.
For your giving
The Malaria Consortium is one of the strongest options for donors who want high-confidence, high-impact giving. The evidence is robust, the cost-effectiveness is in GiveWell's top tier, and the organisation has demonstrated the ability to scale while maintaining quality.
You can donate directly via the Malaria Consortium's website or through GiveWell's recommended charities page. GiveWell's "Maximum Impact Fund" also allocates significantly to SMC when the Malaria Consortium has room for more funding.
One sentence
The Malaria Consortium prevents malaria before it starts, treating 45 million children a year with proven drugs at $7 per child, and it's one of the most cost-effective ways to save a life that currently exists.
Sources used: Malaria Consortium Annual Report and programme data (2024), GiveWell Malaria Consortium cost-effectiveness analysis (2024), Meremikwu et al. "Drugs for preventing malaria in pregnant women and children" (Cochrane Database of Systematic Reviews, 2012, updated 2022), ACCESS-SMC project results (Lancet, 2020), WHO SMC recommendation and guidelines (2012, updated 2023), WHO World Malaria Report (2023), WHO R21/Matrix-M vaccine recommendation (2023). Full links in the planning doc.